Promising new agents in the treatment of non-small cell lung cancer

Martin J. Edelman, David R Gandara

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

Original languageEnglish (US)
Pages (from-to)385-393
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume37
Issue number5
DOIs
StatePublished - Mar 1996

Fingerprint

irinotecan
docetaxel
gemcitabine
Non-Small Cell Lung Carcinoma
Cells
Topotecan
Paclitaxel
Pharmaceutical Preparations
Toxicity
Testing
edatrexate
vinorelbine

Keywords

  • CPT-11
  • Docetaxel
  • Gemcitabine
  • Lung cancer
  • Paclitaxel
  • Topotecan
  • Vinorelbine

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Promising new agents in the treatment of non-small cell lung cancer. / Edelman, Martin J.; Gandara, David R.

In: Cancer Chemotherapy and Pharmacology, Vol. 37, No. 5, 03.1996, p. 385-393.

Research output: Contribution to journalArticle

@article{6a562db835974697bd19e546a639f33e,
title = "Promising new agents in the treatment of non-small cell lung cancer",
abstract = "A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.",
keywords = "CPT-11, Docetaxel, Gemcitabine, Lung cancer, Paclitaxel, Topotecan, Vinorelbine",
author = "Edelman, {Martin J.} and Gandara, {David R}",
year = "1996",
month = "3",
doi = "10.1007/s002800050402",
language = "English (US)",
volume = "37",
pages = "385--393",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Promising new agents in the treatment of non-small cell lung cancer

AU - Edelman, Martin J.

AU - Gandara, David R

PY - 1996/3

Y1 - 1996/3

N2 - A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

AB - A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

KW - CPT-11

KW - Docetaxel

KW - Gemcitabine

KW - Lung cancer

KW - Paclitaxel

KW - Topotecan

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0030020182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030020182&partnerID=8YFLogxK

U2 - 10.1007/s002800050402

DO - 10.1007/s002800050402

M3 - Article

VL - 37

SP - 385

EP - 393

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -